Safety, Tolerability, and Pharmacokinetics of Anaprazole, a Novel Proton Pump Inhibitor, in Healthy Chinese Subjects
Clinical Pharmacology in Drug Development · 2024
DOI: 10.1002/cpdd.1405 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Fangfang Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China. Hauptthemen laut MEDLINE: Healthy Volunteers, Proton Pump Inhibitors, Tablets, Enteric-Coated. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Xuanzhu Biopharm Co..
Abstract (Originalsprache)
Anaprazole, a newly developed oral proton pump inhibitor, was evaluated for safety, tolerability, and pharmacokinetics in healthy Chinese subjects. This study involved administering either anaprazole sodium enteric‐coated tablet or placebo, followed by monitoring the incidence and severity of any adverse events (AEs). The pharmacokinetic parameters of anaprazole, its isomer, and main metabolisms were determined. The results showed that both single‐dose (2.5‐120 mg) and multiple‐dose (20 mg once daily, 40 mg once daily, or 20 mg twice daily) oral administration of anaprazole sodium enteric‐coated tablet were safe and well tolerated. Following single‐dose administration, the median time to reach maximum plasma concentration of anaprazole was between 3.50 and 5.25 hours, with mean elimination half‐life of 1.22‐3.79 hours. The absorption and elimination of anaprazole in the human body appeared to basically follow linear kinetics. After repeated dosing, steady‐state concentrations of anaprazole, its isomer, and primary metabolites were achieved, with a median time to reach maximum plasma concentration of 3‐3.75 hours and a mean elimination half‐life of 1.61‐2.27 hours for anaprazole. There was no significant drug accumulation after multiple‐dose oral administration. In conclusion, anaprazole sodium enteric‐coated tablets were found to be safe and well tolerated in healthy Chinese individuals. Anaprazole is absorbed and metabolized consistently in the human body without any accumulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology and Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.
- Xuanzhu Biopharmaceutical Co., Ltd, Shijiazhuang, China.
Förderung
- Xuanzhu Biopharm Co.
Zitieren
APA
Wang, F., Niu, X., Liu, F., Ma, X., Cheng, F., Xu, H., Wang, L., Xu, Y., & Li, H. (2024). Safety, Tolerability, and Pharmacokinetics of Anaprazole, a Novel Proton Pump Inhibitor, in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1405
Vancouver
Wang F, Niu X, Liu F, Ma X, Cheng F, Xu H, et al. Safety, Tolerability, and Pharmacokinetics of Anaprazole, a Novel Proton Pump Inhibitor, in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1405
BibTeX
@article{Wang2024,
author = {Wang, Fangfang and Niu, Xiaoye and Liu, Fei and Ma, Xifeng and Cheng, Fang and Xu, Haiyan and Wang, Li and Xu, Yanjun and Li, Haiyan},
title = {Safety, Tolerability, and Pharmacokinetics of Anaprazole, a Novel Proton Pump Inhibitor, in Healthy Chinese Subjects},
journal = {Clinical Pharmacology in Drug Development},
year = {2024},
doi = {10.1002/cpdd.1405}
}
EUVIMED